Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmasyntez

Full company profile

uuid000i4xh

Namestring
Pharmasyntez
Legal namestring
Акционерное общество «Фармасинтез»
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Pharmasyntez (Фармасинтез) is a privately held Russian biopharmaceutical group founded in 1997, operating seven GMP-certified manufacturing sites across Irkutsk, St. Petersburg, Tyumen, Ussuriysk, Bratsk, Kaluga, and Moscow (Zelenograd), with more than 6,000 employees. The group runs a vertically integrated full-cycle production model spanning API synthesis (BratskKhimSintez, 250 tonnes/year capacity by 2025), Blow-Fill-Seal infusion solutions (IST-Pharm, Ussuriysk), hormonal drugs at Europe's largest such plant (Pharmasyntez-Tyumen, 500,000 packs/month), fill-finish and lyophilization for oncology cytostatics (Pharmasyntez-Nord, 45 trade names), recombinant long-acting insulin, monoclonal antibodies, and oligonucleotide APIs. Its portfolio targets tuberculosis, HIV/AIDS, oncology, diabetes, hormonal disorders, and chronic renal failure dialysis, with proprietary brands Perylazone (anti-TB, 77 countries), Serogard (anti-adhesion, 140 countries, Phase III), and Kalivid (HIV, 49 countries), backed by 38 Russian/Eurasian patents and 211 international patents.

The core revenue model is Russian federal and regional public procurement for the Vital and Essential Medicines List (ZHNVLP), where domestic API synthesis earns 30-40 procurement points versus 10-15 for secondary packaging. A secondary revenue stream comes from direct government-to-government exports to ministries of health in Syria, Afghanistan, Libya, Belarus, Myanmar, and Brazil, supported by GMP certifications from ANVISA (Brazil), Libya, and Syria. A third stream is medical devices for hemodialysis and peritoneal dialysis produced by Pharmasyntez-Medtech (Kaluga), addressing Russia's 59,000+ dialysis patients currently served by imports.

Strategic posture is anchored to Russia's Pharma 2030 import substitution mandate (90% domestic production of essential medicines target), with aggressive capital deployment of more than 60 billion rubles across Phase 3 St. Petersburg biotechnology (30 billion rubles), Pharmasyntez-Medtech Kaluga (20 billion rubles by 2028), Bratsk Phase 3 (2 billion rubles), Tyumen Phase 2 (4 billion rubles), and a 2 billion ruble China-Russia API joint venture with Zhejiang Hengkan (Hengvey Sintez). Recent moves include a strategic alliance with Cuba's CNEURO for Alzheimer's drug development, Belarus cooperation with Belpharmprom, and a Rospotrebnadzor Category 4 pathogen license enabling in-house viral safety testing for biopharmaceutical products.

Short descriptiontext

Privately held Russian biopharmaceutical group operating seven GMP-certified manufacturing sites, producing full-cycle generic and proprietary drugs (TB, HIV, oncology, diabetes, hormonal) plus dialysis medical devices for Russian public procurement and government-to-government export markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersIrkutsk, Russia
HQ citystring
Irkutsk
HQ countrystring
Russia
HQ regionstring
Europe
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, active pharmaceutical ingredients, biopharmaceutical manufacturing, oncology drug production, hormonal medications
Industry2 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAHAKAB
Peritoneal Dialysis (PD) Systems & Supplies
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Generic Pharmaceuticals Manufacturing
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales (Domestic Russia)
TypeTransaction Fee
Description

Sale of pharmaceutical products through public procurement tenders to Russian federal and regional healthcare systems. Products include oncology drugs, anti-tuberculosis, antiretroviral, hormonal, diabetes, dialysis, and输液 medications. The majority of products are on the Vital and Essential Medicines list (ZHNVLP).

pharmasyntez.com:443
2International Pharmaceutical Exports
TypeTransaction Fee
Description

Direct supply agreements with foreign governments and ministries of health for pharmaceutical products. Export destinations include Syria, Afghanistan, Libya, North Africa, Belarus, Myanmar, Brazil. GMP certifications obtained for multiple international markets.

pharmasyntez.com:443
3Medical Devices (Pharmasyntez-Medtech)
TypeHardware Sales
Description

Production and sale of medical devices including consumables for hemodialysis, peritoneal dialysis equipment and consumables, dialyzers for treatment of chronic renal failure.

pharmasyntez.com:443
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Infrastructure, Operations
Pricing details1 tier
1Public procurement tender pricing for Russian healthcare system
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Pharma 2030 strategy targets 90% domestic production of essential medicines; Russia's $9.2 billion pharmaceutical market; prices regulated under government tender system; compulsory license royalties capped at 0.5% for generic manufacturers.

drugpatentwatch.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Перхлозон® (Perchlazone®)
Description

Anti-tuberculosis drug (TUreoidoiminomethylpyridinium perchlorate) for treating pulmonary tuberculosis including multi-drug resistant forms, patented in 77 countries

pharmasyntez.com
+6 more records
Core offering1 text field

Pharmasyntez is a vertically integrated Russian biopharmaceutical manufacturer operating full-cycle production from active pharmaceutical ingredient (API) synthesis to finished dosage forms. The group produces generic and innovative medicines across tuberculosis, HIV/AIDS, oncology, diabetes, hormonal, and dialysis therapeutic areas through seven manufacturing sites in Russia (Irkutsk, St. Petersburg, Tyumen, Ussuriysk, Bratsk, Kaluga, and Moscow).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Pharmasyntez-Nord captured nearly 100% of domestic semaglutide market within 12 months of compulsory license (extrapolated from market data)
+4 more records
Product overview1 text field

Pharmasyntez Group is one of Russia's leading biopharmaceutical companies, operating as a multi-site manufacturing conglomerate with seven production facilities across Russia (Irkutsk, St. Petersburg, Tyumen, Ussuriysk, Bratsk, Kaluga, and Moscow). The portfolio is organized around therapeutic areas — oncology, tuberculosis, HIV/AIDS, diabetes, and hormonal disorders — and includes both proprietary innovative drugs and generic/biosimilar products. Key innovative brands include Pakhlozon (tuberculosis, patented in 77 countries), Serogard (anti-adhesion, Phase III), Kalidavir (HIV), Saterex (diabetes, Russia's only domestically produced formulation), and Ziflukort (fludrocortisone). Core generic portfolios span cytotoxic oncology drugs (45 trade names at Pharmasyntez-Nord), hormonal preparations (24 trade names at Pharmasyntez-Tyumen), infusion solutions via Blow-Fill-Seal (IST-Pharm, Ussuriysk), and active pharmaceutical substances (APIs) for anti-tuberculosis, antiretroviral, and anti-oncology drugs (Bratskkhimsintez). Pharmasyntez-Medtech (Kaluga) extends the group into medical devices for dialysis. Pipeline includes an Alzheimer's therapy with Cuba's CNEURO and multiple international export expansions.

Product and service1 record
1Pakhlozon (Перхлозон)
Scale indicator17 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-05
Description

Memorandum of cooperation signed between Pharmasyntez Group and RWB Zdorovye for joint projects in women's health and reproductive medicine, and development of healthcare sovereignty solutions for Russia. Companies agreed to jointly develop a platform combining patient support tools, digital services, and education on women's health, reproductive medicine, and prevention of endocrine and metabolic disorders.

2Government of St. Petersburg
Strategic tierCoreTypeOthersAnnounced on2026-06-05
Description

Pharmasyntez-Nord and the Government of St. Petersburg signed investment agreement for third phase of biotechnological production complex. Government provides consulting, informational support, and assistance with negotiations and joint events. Pharmasyntez-Nord invests 30 billion rubles creating 1,000+ jobs. Signed in presence of Minister of Industry and Trade Anton Alikhanov and Governor Alexander Beglov.

pharmasyntez.com
3Zhejiang Hengkan Pharmaceutical (Чжэцзян Хэнкан Фармасьютикал)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

BratskKhimSintez (part of Pharmasyntez Group) and Chinese Zhejiang Hengkan Pharmaceutical signed an agreement to create a joint venture named Hengvey Sintez for development and synthesis of active pharmaceutical substances. Investment exceeds 2 billion rubles. First production complex planned in Bratsk, Irkutsk Oblast. The joint venture will focus on APIs for drugs treating socially significant diseases, strengthening pharmaceutical sovereignty of Russia.

pharmasyntez.com
4Government of Irkutsk Oblast
Strategic tierCoreTypeOthersAnnounced on2026-06-03
Description

Governor Igor Kobzev and Pharmasyntez President Vikram Punya signed additional agreement to existing social-economic cooperation contract at St. Petersburg Economic Forum. Document fixes tax contributions to regional budget for 2026-2027 and list of social initiatives supported by the company. Pharmasyntez is one of the largest taxpayers and reliable social partner in the Irkutsk region.

pharmasyntez.com
Strategic tierMinorTypeOthersAnnounced on2026-05-27
Description

Pharmasyntez Group agreed with Afghan Ministry of Health to begin supplies of pharmaceutical products to Afghanistan. First batches planned for delivery within two months. This expands export geography and international presence of the Russian manufacturer.

6Cuban Center for Neuroscience CNEURO (BioCubaFarma)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Pharmasyntez Group and Cuban Center for Neuroscience CNEURO (part of BioCubaFarma conglomerate) announced start of a joint project to create a new drug for treatment of Alzheimer's disease. This represents a strategic alliance combining Pharmasyntez's manufacturing capabilities with CNEURO's neuroscience research expertise.

pharmasyntez.com
7Government of Tyumen Oblast
Strategic tierMinorTypeOthersAnnounced on2025-06-02
Description

Pharmasyntez and Tyumen Oblast Government signed cooperation agreement for development of regional culture. Governor Alexander Moor and Pharmasyntez President Vikram Punya signed the document. Partnership includes joint cultural initiatives and Tyumen Philharmonic's international performances including in China.

pharmasyntez.com
8Belpharmprom (Belarusian Pharmaceutical Industry Holding)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-27
Description

Memorandum of understanding signed between Pharmasyntez and Belpharmprom to develop strategic cooperation in pharmaceutical industry, joint implementation of innovative solutions, and strengthening of partnership ties. Pharmasyntez has two strategic production projects in Tyumen Oblast for hypoglycemic and hormonal drugs. Negotiations conducted with Belpharmprom subsidiaries including RUP Belmedpreparaty, OAO BZMP, and OAO Nesvizhsky Zavod Meditsinskikh Preparatov.

pharmasyntez.com
9Libya Ministry of Health
Strategic tierMinorTypeOthersAnnounced on2025-03-23
Description

Pharmasyntez and Pharmasyntez-Tyumen passed GMP inspection by Libyan Ministry of Health in December 2024; certificate received March 12, 2025. This opens the way for supplies of high-quality medications to Libya. Pharmasyntez-Tyumen is the largest hormonal drug manufacturing plant in Europe.

pharmasyntez.com
Strategic tierMinorTypeOthersAnnounced on2024-12-28
Description

Pharmasyntez-Nord became the first Russian company to receive ANVISA GMP certification for finished dosage form manufacturing in Brazil — a historic achievement for the Russian pharmaceutical industry in South America. Plans to begin drug registration process in Brazil in Q1 2025 and expand presence across the LATAM region.

11Bratsk City Administration
Strategic tierMinorTypeOthersAnnounced on2024-12-10
Description

BratskKhimSintez and Bratsk city administration signed social-economic partnership agreement. Mayor Alexander Dubrovin and General Director Ivan Dratsky signed the agreement. BratskKhimSintez will finance various city-initiated projects in the coming year, supporting local social and infrastructure development.

pharmasyntez.com
Strategic tierMinorTypeOthersAnnounced on2024-03-01
Description

Pharmasyntez became one of the first Russian companies to supply oncology medications to Syria. GMP inspection passed in July 2023; company registered in Syria in March 2024. Production capacity allows full coverage of Syria's needs for socially significant medicines.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Russian biotech company developing and manufacturing biosimilars, monoclonal antibodies, and innovative biologics. Directly comparable as a domestic manufacturer competing on similar import-substitution themes in oncology and autoimmune diseases.

TypeDirect peer
Description

Russian pharmaceutical manufacturer producing branded generic and original drugs across therapeutic areas. Comparable in scale, domestic-market focus, and product portfolio breadth serving the same Russian government channels.

TypeEmerging player
Description

Russian pharmaceutical and biotech company focused on generics and biosimilars including insulin products. Comparable as a domestic biosimilar/generics player overlapping in diabetes and chronic disease therapy areas.

TypeRegional player
Description

Slovenian-based generic pharmaceutical manufacturer with strong presence across CEE/CIS markets including Russia. Comparable as a generics-heavy multi-site producer targeting similar Eastern European and CIS customers.

TypeDirect peer
Description

Russian pharmaceutical manufacturer with portfolio spanning oncology, anti-infectives, and hospital products. Comparable therapeutic mix, GxP-certified domestic production, and similar reliance on Russian public procurement and import substitution.

6Polysan
TypeDirect peer
Description

Russian pharmaceutical manufacturer with focus on generics, anti-infectives, and hospital products. Comparable domestic manufacturer serving Russian federal procurement with similar therapeutic mix.

TypeDirect peer
Description

Russian pharmaceutical manufacturer producing generic and specialty drugs, including oncology and hospital injectables. Directly comparable finished-dose generic manufacturer with similar customer base and distribution channels.

TypeDirect peer
Description

Russian biotech firm focused on biosimilars, orphan drugs, and blood products. Closely comparable biologics/biosimilars portfolio and domestic manufacturing footprint serving the same Russian healthcare customer base.

TypeBroad incumbent
Description

Largest Russian pharmaceutical company by sales, with broad generics and consumer health portfolio. Comparable as a leading Russian pharma but materially larger and more diversified across OTC, consumer health, and Rx categories.

TypeRegional player
Description

Hungarian-headquartered pharmaceutical company with generics, biosimilars, and women's health portfolio and historic strength in CEE/CIS. Comparable in generics manufacturing scale and regional market orientation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmasyntez

Generic Pharmaceuticals Manufacturingpharmasyntez.com

Privately held Russian biopharmaceutical group operating seven GMP-certified manufacturing sites, producing full-cycle generic and proprietary drugs (TB, HIV, oncology, diabetes, hormonal) plus dialysis medical devices for Russian public procurement and government-to-government export markets.

What Pharmasyntez does

Pharmasyntez (Фармасинтез) is a privately held Russian biopharmaceutical group founded in 1997, operating seven GMP-certified manufacturing sites across Irkutsk, St. Petersburg, Tyumen, Ussuriysk, Bratsk, Kaluga, and Moscow (Zelenograd), with more than 6,000 employees. The group runs a vertically integrated full-cycle production model spanning API synthesis (BratskKhimSintez, 250 tonnes/year capacity by 2025), Blow-Fill-Seal infusion solutions (IST-Pharm, Ussuriysk), hormonal drugs at Europe's largest such plant (Pharmasyntez-Tyumen, 500,000 packs/month), fill-finish and lyophilization for oncology cytostatics (Pharmasyntez-Nord, 45 trade names), recombinant long-acting insulin, monoclonal antibodies, and oligonucleotide APIs. Its portfolio targets tuberculosis, HIV/AIDS, oncology, diabetes, hormonal disorders, and chronic renal failure dialysis, with proprietary brands Perylazone (anti-TB, 77 countries), Serogard (anti-adhesion, 140 countries, Phase III), and Kalivid (HIV, 49 countries), backed by 38 Russian/Eurasian patents and 211 international patents.

The core revenue model is Russian federal and regional public procurement for the Vital and Essential Medicines List (ZHNVLP), where domestic API synthesis earns 30-40 procurement points versus 10-15 for secondary packaging. A secondary revenue stream comes from direct government-to-government exports to ministries of health in Syria, Afghanistan, Libya, Belarus, Myanmar, and Brazil, supported by GMP certifications from ANVISA (Brazil), Libya, and Syria. A third stream is medical devices for hemodialysis and peritoneal dialysis produced by Pharmasyntez-Medtech (Kaluga), addressing Russia's 59,000+ dialysis patients currently served by imports.

Strategic posture is anchored to Russia's Pharma 2030 import substitution mandate (90% domestic production of essential medicines target), with aggressive capital deployment of more than 60 billion rubles across Phase 3 St. Petersburg biotechnology (30 billion rubles), Pharmasyntez-Medtech Kaluga (20 billion rubles by 2028), Bratsk Phase 3 (2 billion rubles), Tyumen Phase 2 (4 billion rubles), and a 2 billion ruble China-Russia API joint venture with Zhejiang Hengkan (Hengvey Sintez). Recent moves include a strategic alliance with Cuba's CNEURO for Alzheimer's drug development, Belarus cooperation with Belpharmprom, and a Rospotrebnadzor Category 4 pathogen license enabling in-house viral safety testing for biopharmaceutical products.

Pharmasyntez firmographics

Firmographics
Name
Pharmasyntez
Legal name
Акционерное общество «Фармасинтез»
Website
https://pharmasyntez.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
101–250 employees
Short description
Privately held Russian biopharmaceutical group operating seven GMP-certified manufacturing sites, producing full-cycle generic and proprietary drugs (TB, HIV, oncology, diabetes, hormonal) plus dialysis medical devices for Russian public procurement and government-to-government export markets.
Ownership category
akta.pro rank

Pharmasyntez industry classification

Industry
Product category
Generic Pharmaceuticals Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAHAKAB
Peritoneal Dialysis (PD) Systems & Supplies

Keywords

  • Generic pharmaceuticals
  • Active pharmaceutical ingredients
  • Biopharmaceutical manufacturing
  • Oncology drug production
  • Hormonal medications

Where Pharmasyntez is headquartered

Location

Headquarters

HQ city
Irkutsk
HQ country
Russia
HQ region
Europe

Offices8 records

Markets served

Pharmasyntez business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Infrastructure, Operations

Revenue model

  1. Pharmaceutical Product Sales (Domestic Russia): Sale of pharmaceutical products through public procurement tenders to Russian federal and regional healthcare systems. Products include oncology drugs, anti-tuberculosis, antiretroviral, hormonal, diabetes, dialysis, and输液 medications. The majority of products are on the Vital and Essential Medicines list (ZHNVLP).
  2. International Pharmaceutical Exports: Direct supply agreements with foreign governments and ministries of health for pharmaceutical products. Export destinations include Syria, Afghanistan, Libya, North Africa, Belarus, Myanmar, Brazil. GMP certifications obtained for multiple international markets.
  3. Medical Devices (Pharmasyntez-Medtech): Production and sale of medical devices including consumables for hemodialysis, peritoneal dialysis equipment and consumables, dialyzers for treatment of chronic renal failure.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goPublic procurement tender pricing for Russian healthcare system

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Pharmasyntez product offering

Product offering

Core offering

Pharmasyntez is a vertically integrated Russian biopharmaceutical manufacturer operating full-cycle production from active pharmaceutical ingredient (API) synthesis to finished dosage forms. The group produces generic and innovative medicines across tuberculosis, HIV/AIDS, oncology, diabetes, hormonal, and dialysis therapeutic areas through seven manufacturing sites in Russia (Irkutsk, St. Petersburg, Tyumen, Ussuriysk, Bratsk, Kaluga, and Moscow).

Product overview

Pharmasyntez Group is one of Russia's leading biopharmaceutical companies, operating as a multi-site manufacturing conglomerate with seven production facilities across Russia (Irkutsk, St. Petersburg, Tyumen, Ussuriysk, Bratsk, Kaluga, and Moscow). The portfolio is organized around therapeutic areas — oncology, tuberculosis, HIV/AIDS, diabetes, and hormonal disorders — and includes both proprietary innovative drugs and generic/biosimilar products. Key innovative brands include Pakhlozon (tuberculosis, patented in 77 countries), Serogard (anti-adhesion, Phase III), Kalidavir (HIV), Saterex (diabetes, Russia's only domestically produced formulation), and Ziflukort (fludrocortisone). Core generic portfolios span cytotoxic oncology drugs (45 trade names at Pharmasyntez-Nord), hormonal preparations (24 trade names at Pharmasyntez-Tyumen), infusion solutions via Blow-Fill-Seal (IST-Pharm, Ussuriysk), and active pharmaceutical substances (APIs) for anti-tuberculosis, antiretroviral, and anti-oncology drugs (Bratskkhimsintez). Pharmasyntez-Medtech (Kaluga) extends the group into medical devices for dialysis. Pipeline includes an Alzheimer's therapy with Cuba's CNEURO and multiple international export expansions.

Differentiator

Problem solved

Functional benefit

Brands

  • Перхлозон® (Perchlazone®): Anti-tuberculosis drug (TUreoidoiminomethylpyridinium perchlorate) for treating pulmonary tuberculosis including multi-drug resistant forms, patented in 77 countries
  • Серогард® (Serogard®)
  • Калидавир® (Kalidavir®)
  • Сатерекс (Satyereks)
  • Зифлукорт (Ziflukort)
  • Протуб-4®
  • Протуб-2®

Products and services

  • Pakhlozon (Перхлозон)

Quantifiable outcome

  • Pharmasyntez-Nord captured nearly 100% of domestic semaglutide market within 12 months of compulsory license (extrapolated from market data)
  • +4 more outcomes

Companies that use Pharmasyntez

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Pharmasyntez technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Pharmasyntez partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered minor and core.

  • RWB Zdorovye (RWB Health)minorStrategic or Co-development Partner · 5 June 2026Memorandum of cooperation signed between Pharmasyntez Group and RWB Zdorovye for joint projects in women's health and reproductive medicine, and development of healthcare sovereignty solutions for Russia. Companies agreed to jointly develop a platform combining patient support tools, digital services, and education on women's health, reproductive medicine, and prevention of endocrine and metabolic disorders.
  • Government of St. PetersburgcoreOthers · 5 June 2026Pharmasyntez-Nord and the Government of St. Petersburg signed investment agreement for third phase of biotechnological production complex. Government provides consulting, informational support, and assistance with negotiations and joint events. Pharmasyntez-Nord invests 30 billion rubles creating 1,000+ jobs. Signed in presence of Minister of Industry and Trade Anton Alikhanov and Governor Alexander Beglov.
  • Zhejiang Hengkan Pharmaceutical (Чжэцзян Хэнкан Фармасьютикал)coreStrategic or Co-development Partner · 3 June 2026BratskKhimSintez (part of Pharmasyntez Group) and Chinese Zhejiang Hengkan Pharmaceutical signed an agreement to create a joint venture named Hengvey Sintez for development and synthesis of active pharmaceutical substances. Investment exceeds 2 billion rubles. First production complex planned in Bratsk, Irkutsk Oblast. The joint venture will focus on APIs for drugs treating socially significant diseases, strengthening pharmaceutical sovereignty of Russia.
  • Government of Irkutsk OblastcoreOthers · 3 June 2026Governor Igor Kobzev and Pharmasyntez President Vikram Punya signed additional agreement to existing social-economic cooperation contract at St. Petersburg Economic Forum. Document fixes tax contributions to regional budget for 2026-2027 and list of social initiatives supported by the company. Pharmasyntez is one of the largest taxpayers and reliable social partner in the Irkutsk region.
  • Afghanistan Ministry of HealthminorOthers · 27 May 2026Pharmasyntez Group agreed with Afghan Ministry of Health to begin supplies of pharmaceutical products to Afghanistan. First batches planned for delivery within two months. This expands export geography and international presence of the Russian manufacturer.
  • Cuban Center for Neuroscience CNEURO (BioCubaFarma)coreStrategic or Co-development Partner · 11 February 2026Pharmasyntez Group and Cuban Center for Neuroscience CNEURO (part of BioCubaFarma conglomerate) announced start of a joint project to create a new drug for treatment of Alzheimer's disease. This represents a strategic alliance combining Pharmasyntez's manufacturing capabilities with CNEURO's neuroscience research expertise.
  • Government of Tyumen OblastminorOthers · 2 June 2025Pharmasyntez and Tyumen Oblast Government signed cooperation agreement for development of regional culture. Governor Alexander Moor and Pharmasyntez President Vikram Punya signed the document. Partnership includes joint cultural initiatives and Tyumen Philharmonic's international performances including in China.
  • Belpharmprom (Belarusian Pharmaceutical Industry Holding)coreStrategic or Co-development Partner · 27 May 2025Memorandum of understanding signed between Pharmasyntez and Belpharmprom to develop strategic cooperation in pharmaceutical industry, joint implementation of innovative solutions, and strengthening of partnership ties. Pharmasyntez has two strategic production projects in Tyumen Oblast for hypoglycemic and hormonal drugs. Negotiations conducted with Belpharmprom subsidiaries including RUP Belmedpreparaty, OAO BZMP, and OAO Nesvizhsky Zavod Meditsinskikh Preparatov.
  • Libya Ministry of HealthminorOthers · 23 March 2025Pharmasyntez and Pharmasyntez-Tyumen passed GMP inspection by Libyan Ministry of Health in December 2024; certificate received March 12, 2025. This opens the way for supplies of high-quality medications to Libya. Pharmasyntez-Tyumen is the largest hormonal drug manufacturing plant in Europe.
  • ANVISA (Brazilian Health Regulatory Agency)minorOthers · 28 December 2024Pharmasyntez-Nord became the first Russian company to receive ANVISA GMP certification for finished dosage form manufacturing in Brazil — a historic achievement for the Russian pharmaceutical industry in South America. Plans to begin drug registration process in Brazil in Q1 2025 and expand presence across the LATAM region.
  • Bratsk City AdministrationminorOthers · 10 December 2024BratskKhimSintez and Bratsk city administration signed social-economic partnership agreement. Mayor Alexander Dubrovin and General Director Ivan Dratsky signed the agreement. BratskKhimSintez will finance various city-initiated projects in the coming year, supporting local social and infrastructure development.
  • Syrian Ministry of HealthminorOthers · 1 March 2024Pharmasyntez became one of the first Russian companies to supply oncology medications to Syria. GMP inspection passed in July 2023; company registered in Syria in March 2024. Production capacity allows full coverage of Syria's needs for socially significant medicines.

Scale indicators17 records

Recent moves11 records

Expansion highlights6 records

Pharmasyntez competitors and assessment

Company assessment

Direct peers

  • BIOCAD: Russian biotech company developing and manufacturing biosimilars, monoclonal antibodies, and innovative biologics. Directly comparable as a domestic manufacturer competing on similar import-substitution themes in oncology and autoimmune diseases.
  • Valenta Pharm: Russian pharmaceutical manufacturer producing branded generic and original drugs across therapeutic areas. Comparable in scale, domestic-market focus, and product portfolio breadth serving the same Russian government channels.
  • R-Pharm: Russian pharmaceutical manufacturer with portfolio spanning oncology, anti-infectives, and hospital products. Comparable therapeutic mix, GxP-certified domestic production, and similar reliance on Russian public procurement and import substitution.
  • Polysan: Russian pharmaceutical manufacturer with focus on generics, anti-infectives, and hospital products. Comparable domestic manufacturer serving Russian federal procurement with similar therapeutic mix.
  • Sotex: Russian pharmaceutical manufacturer producing generic and specialty drugs, including oncology and hospital injectables. Directly comparable finished-dose generic manufacturer with similar customer base and distribution channels.
  • Generium: Russian biotech firm focused on biosimilars, orphan drugs, and blood products. Closely comparable biologics/biosimilars portfolio and domestic manufacturing footprint serving the same Russian healthcare customer base.

Emerging players

  • NovaMedika: Russian pharmaceutical and biotech company focused on generics and biosimilars including insulin products. Comparable as a domestic biosimilar/generics player overlapping in diabetes and chronic disease therapy areas.

Regional players

  • KRKA: Slovenian-based generic pharmaceutical manufacturer with strong presence across CEE/CIS markets including Russia. Comparable as a generics-heavy multi-site producer targeting similar Eastern European and CIS customers.
  • Gedeon Richter: Hungarian-headquartered pharmaceutical company with generics, biosimilars, and women's health portfolio and historic strength in CEE/CIS. Comparable in generics manufacturing scale and regional market orientation.

Broad incumbents

  • Pharmstandard: Largest Russian pharmaceutical company by sales, with broad generics and consumer health portfolio. Comparable as a leading Russian pharma but materially larger and more diversified across OTC, consumer health, and Rx categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Pharmasyntez compliance and trust

Trust signal

Compliance6 records

Pharmasyntez financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmasyntez leadership team

Management profile

Number of profiles

Profiles12 records

Pharmasyntez subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Pharmasyntez funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmasyntez M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmasyntez

What does Pharmasyntez do?

Pharmasyntez is a vertically integrated Russian biopharmaceutical manufacturer operating full-cycle production from active pharmaceutical ingredient (API) synthesis to finished dosage forms. The group produces generic and innovative medicines across tuberculosis, HIV/AIDS, oncology, diabetes, hormonal, and dialysis therapeutic areas through seven manufacturing sites in Russia (Irkutsk, St. Petersburg, Tyumen, Ussuriysk, Bratsk, Kaluga, and Moscow).

Is Pharmasyntez a public or private company?

Pharmasyntez is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Pharmasyntez founded?

Pharmasyntez was founded in 1997. It employs 101 to 250 people.

Where is Pharmasyntez based?

Pharmasyntez is headquartered in Irkutsk, Russia, in the Europe region.

How does Pharmasyntez make money?

Three revenue lines are on record. Pharmaceutical Product Sales (Domestic Russia) is the primary driver. The others are international Pharmaceutical Exports and medical Devices (Pharmasyntez-Medtech).

Who are Pharmasyntez's main competitors?

Direct peers on record are BIOCAD, Valenta Pharm, R-Pharm, Polysan, Sotex and Generium. NovaMedika is listed as an emerging player. Regional players are KRKA and Gedeon Richter. Pharmstandard is listed as a broad incumbent.

Does Pharmasyntez have an API?

No public API is recorded for Pharmasyntez.

What industry is Pharmasyntez in?

Pharmasyntez's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAHAKAB, Peritoneal Dialysis (PD) Systems & Supplies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Agence EcofinProduits pharmaceutiques : le russe Pharmasyntez veut étendre sa présence en AfriqueRussian pharmaceutical group Pharmasyntez plans to expand in Africa, having certified two plants for Libyan exports in March 2025. It targeted Morocco and Mali in May 2026, with Africa's pharmaceutical imports reaching $14 billion in 2025. The group aims to register its drugs and partner with local distributors.TASSRussian stock market ends week lower as major indices declineThe Moscow Exchange (MOEX) Index declined 0.2% and the RTS Index fell 1.12% on Friday, driven by cautious sentiment stemming from stalled Ukraine negotiations and falling oil prices. Eurotrans shares led declines with a 6.1% drop amid bond default anxieties, while Pharmsintez gained 3.6% following positive financial results.Trade BrainsPharma Stock Soars 13% After Signing Licensing and Supply Deal With Pharmasyntez JSC, RussiaOrchid Pharma Ltd. has entered into a licensing and supply agreement with Pharmasyntez JSC in Russia for the commercialization of Exblifep®, a novel antibiotic, which is expected to enhance Orchid Pharma's presence and market opportunities. The deal is estimated to generate approximately USD 178 million over the first 10 years, supported by growing demand for advanced antibiotics in Russia. This partnership could potentially drive Orchid Pharma's next phase of growth and revenue significantly.MarketScreenerIndian shares set to open lower as US-Iran tensions lift oil pricesIndian shares were set to open lower on Wednesday as renewed U.S.-Iran tensions lifted crude oil prices, a key risk for India. GIFT Nifty futures traded at 24,235, below Tuesday's close of 24,398.7, while Brent crude rose 2% to about $76 a barrel.ReutersRussian court rejects U.S firm's lawsuit over COVID-19 drug remdesivirRussia's Supreme Court rejected Gilead Sciences' lawsuit over a compulsory licence allowing Pharmasyntez to produce remdesivir without Gilead's consent. The government said the move was in Russia's security interests, with compensation amount unspecified. Gilead called the licence unnecessary and counterproductive.PR NewswireOasmia presenta una solicitud de autorización de marketing para Apealea®Oasmia Pharmaceutical AB submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Apealea, a new paclitaxel-based cancer treatment formulated using its proprietary XR-17 micellar nanoparticle platform, seeking approval for epithelial ovarian cancer treatment in combination with carboplatin. The EU cytostatic market exceeds €5 billion annually, and Apealea demonstrated non-inferiority to Taxol in a Phase III trial involving 789 patients across 16 countries, with advantages including no pre-medication requirement, one-hour infusion time, and potentially reduced neuropathy risk. The product is already approved and launched in Russia since April 2015 through Oasmia's partner Pharmasyntez.PR NewswireOasmia Has Submitted a Marketing Authorization Application to the European Medicines Agency for Its Lead Cancer Product Apealea® (Paclical®)Oasmia Pharmaceutical AB has submitted a marketing authorization application to the European Medicines Agency for Apealea, a novel paclitaxel formulation intended for treating epithelial ovarian cancer. The application is based on Phase III study results involving 789 patients across 16 countries, which demonstrated non-inferiority compared to the standard treatment Taxol. This follows the product's prior approval and launch in the Russian Federation through partner Pharmasyntez.PR NewswireOasmias har ansökt om marknadsföringstillstånd hos den Europeiska läkemedelsmyndigheten (EMA) för cancerläkemedlet Apealea® (Paclical®)Oasmia Pharmaceutical AB announced on February 8, 2016, that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for Apealea (also known as Paclical), a cancer drug based on its XR-17 technology for treatment of epithelial ovarian cancer in combination with carboplatin. The application is based on a pivotal Phase III study conducted in 16 countries with 789 patients, demonstrating non-inferiority to Taxol with potential advantages including no need for premedication, one-hour infusion time, and possibly reduced risk of neuropathy. The product is already approved and launched in Russia by Oasmia's partner Pharmasyntez, with the European cytostatics market estimated at over five billion euros annually.PR NewswireOasmia's Lead Cancer Product Paclical® Receives Market Approval in the Russian FederationOasmia's lead cancer product Paclical received market authorization in the Russian Federation by the Ministry of Health. It is the first water-soluble paclitaxel drug approved, planned for launch in the second half of 2015. The Russia-based distributor Pharmasyntez will market it in Russia and CIS countries.PR Newswire APACOasmia's Lead Cancer Product Paclical® Receives Market Approval in the Russian FederationOasmia's lead cancer product Paclical received market authorization in the Russian Federation by the Russian Ministry of Health. It is the first water-soluble paclitaxel drug approved, planned for launch in the second half of 2015. The Russia-based distributor Pharmasyntez will market it in Russia and CIS countries.